The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00675090




Registration number
NCT00675090
Ethics application status
Date submitted
24/04/2008
Date registered
8/05/2008
Date last updated
7/07/2017

Titles & IDs
Public title
Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease
Scientific title
A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective Histamine H3 Receptor Antagonist
Secondary ID [1] 0 0
H3B109689
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GSK239512
Treatment: Drugs - Placebo

Experimental: GSK239512 - GSK239512 oral tablets

Placebo Comparator: Placebo - Placebo to match tablets


Treatment: Drugs: GSK239512
GSK239512 oral tablets once a day

Treatment: Drugs: Placebo
Placebo tablets to match once a day

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety and tolerability as measured by adverse events, vital signs clinical laboratory measurements and validated clinical assessment scales.
Timepoint [1] 0 0
Days 8, 15, 22 and 29
Secondary outcome [1] 0 0
Pharmacodynamics measured by computerized cognitive tests and validated clinical rating scales. Also investigating the Pharmacokineticsat trough concentrations (Cmin) after GSK239512 repeat dosing on days 8, 15, 22 and 29 and 15.
Timepoint [1] 0 0
days 8, 15, 22 and 29

Eligibility
Key inclusion criteria
- Male or female subjects with a clinical diagnosis of probable Alzheimer's disease

- The subject has an MMSE score at screening of 12 to 26 for Part A and 16-26 for Part
B.

- Age = 50 and above.

- If female, the subject must be post-menopausal (i.e. 12 months without menstrual
period) or surgically sterile.

- Male subjects must be willing to abstain from sexual intercourse with pregnant or
lactating women; or be willing to use a condom/spermicide in addition to having their
female partner use another form of contraception if the woman could become pregnant,
from the time of the first dose of GSK239512 until 84 days following completion of the
study.

- The subject has the ability to comply with the study procedures.

- The subject has a permanent caregiver and is willing to attend all study visits for
Parts A and B.

- The subject has provided full written informed consent prior to the performance of any
protocol specific procedure, or if unable to provide informed consent due to cognitive
status, full written informed consent on behalf of the subject has been provided by a
legally acceptable representative.

- The caregiver has provided his / her written consent prior to the performance of any
protocol specific procedure.
Minimum age
50 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- In the opinion of the investigator, following review of CT/MRI scans in the past 12
months and completion of neurological review there could be other probable causes of
dementia

- History of significant psychiatric illness such as schizophrenia or bipolar affective
disorder that in the opinion of the Investigator would interfere with participation in
the study, or current depression (a score of =8 on the Cornell Scale for Depression in
Dementia), or subjects with other psychiatric features in their AD which would in the
opinion of the investigator, would increase risk to safety.

- History of significant sleep disturbance, for example, when it is associated with
nocturnal wandering, nocturnal confusion / disorientation / agitation, which in the
opinion of the investigator, may increase safety risk.

- History or presence of known or suspected seizures, unexplained significant loss of
consciousness within last 6 months. Subjects who had febrile seizures in childhood may
be included if these ceased by age 10 and they have had no other type of seizure in
their medical history and have not been on anti-epileptic medications.

- History or presence of significant cardiovascular, gastro-intestinal, hepatic, or
renal disease or other condition known to interfere with the absorption, distribution,
metabolism, or excretion of drugs, or any other clinically relevant abnormality,
medical or psychiatric condition, which, in the opinion of the Investigator, makes the
subject unsuitable for inclusion in the study.

- History of alcohol or other substance abuse, according to the Diagnostic and
Statistical Manual of Mental Disorders - Substance related disorders (DSM-IV)
criteria.

- Clinically significant abnormalities in laboratory tests, including subjects with
active liver disease or uncontrolled thyroid disease.

- Uncontrolled hypertension with systolic BP =160 and/or diastolic =95 mmHg. Subjects
with controlled hypertension with systolic BP < 160 mmHg and diastolic <95 mmHg for at
least 4 weeks are acceptable.

- Systolic BP <100 mmHg and/or diastolic <60 mmHg.

- Subjects with ECG criteria outside ranges specified in the protocol

- History of hypersensitivity to GSK239512 or its excipients.

- Treatment with cholinesterase inhibitors, (including Tacrine), memantine or selegiline
within the previous month. No patients with AD who are already on these medications at
the time of screening will be recruited, as it would be unethical to withdraw these
medications for study participation. Only AD subjects who are not yet on these
medications, or who have withdrawn from these medications for other reasons
previously, may be enrolled into this study.

- Subjects who are currently taking or who have taken in the last month anti-psychotic
drugs (typical or atypical dopaminergic antagonists or modulators) or mood
stabilization drugs (including SSRI, DNRI, SNRI, MAO inhibitors, tricyclic
antidepressants, lithium, valproate, carbamazepine).

- Subjects who are currently taking Pgp inhibitors or any CYP3A4 inhibitors.

- Subjects on chronic sedative medications (= 4 days per week for the past 4 weeks).

- Subject or caregiver is an immediate family member or employee of the participating
Investigator, any of the participating site staff or GSK staff.

- Has received any other investigational treatment in the previous 3 months.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
GSK Investigational Site - Randwick
Recruitment hospital [2] 0 0
GSK Investigational Site - Heidelberg Heights
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
3084 - Heidelberg Heights
Recruitment outside Australia
Country [1] 0 0
Czechia
State/province [1] 0 0
Prague 10
Country [2] 0 0
Korea, Republic of
State/province [2] 0 0
Seoul
Country [3] 0 0
United Kingdom
State/province [3] 0 0
Cambridgeshire
Country [4] 0 0
United Kingdom
State/province [4] 0 0
London
Country [5] 0 0
United Kingdom
State/province [5] 0 0
Southall

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a safety and tolerability study to investigate the effect of GSK239512 on mild to
moderate Alzheimers disease patients. The dose of GSK239512 will be titrated to reach the
most well tolerated dose in the patients.
Trial website
https://clinicaltrials.gov/show/NCT00675090
Trial related presentations / publications
Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R. The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. Curr Alzheimer Res. 2013 Mar;10(3):240-51.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications